Clinical Trial Update: Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating carboplatin and paclitaxel with or without ISIS 3521 in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• ISIS 3521 (LY900003)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Lung Cancer | Phase 3 | Status: COMPLETED